Dan Skovronsky, Eli Lilly & Company's CSO and CMO

Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug class

While Bio­gen is still fight­ing to save its con­tro­ver­sial drug Aduhelm from drown­ing in crit­i­cism, Eli Lil­ly ex­ecs echoed for­mer FDA com­mis­sion­er Scott Got­tlieb’s com­ments from last week in the phar­ma’s Q4 earn­ings call this morn­ing con­cern­ing its amy­loid-tar­get­ed Alzheimer’s drug do­nanemab — and how the de­ci­sion by CMS to re­strict re­im­burse­ments on all an­ti-amy­loid mAbs could put this field of re­search in jeop­ardy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.